BioCatalystWatch
KRROWorkspace / KRRO / OverviewCompany library
Price
Market cap
Next catalystBegin UCD patient dosing in ANCHOR Part 2 in H1 2027, subject to regulatory clearance to proceedKRRO-121 — ANCHOR Part 2, UCD patients · Trial initiationSEC filing ↗
Cash

Chart & Events

Candle interval

Core Clinical

KRRO-111

SERPINA1/AAT mRNA

Upcoming / outlook

KRRO-121

Glutamine synthetase (GS) RNA

PreINDP1P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

KRRO-111

SERPINA1/AAT mRNA

Upcoming / outlook

KRRO-121

Glutamine synthetase (GS) RNA

PreINDP1P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Other pipelines

KRRO-121

Glutamine synthetase (GS) RNA

PreINDP1P2P3FilingApproved
KRRO-121

Glutamine synthetase (GS) RNA

ALS program targeting TDP43

TDP-43

PreINDP1P2P3FilingApproved
AMPKγ1 longevity/liver program

AMPKγ1

PreINDP1P2P3FilingApproved

History / paused

SERPINA1 RNA

PreINDP1P2P3FilingApproved

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Company funding outlook

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Operating
Investing
Financing

Reported shares and borrowings

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

KRRO SEC archive